← Leaderboards
Robert E. Johnston
University Of North Carolina Chapel Hill
$11,943,669
Attributed
$11,943,669
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–15$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$29,104,889 · 15
By mechanism
P01$18,926,875 · 6
U01$5,173,917 · 1
R01$4,075,947 · 4
R41$532,838 · 1
P51$395,312 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Ralph S Baric$89,182,261
- Laura J White$5,803,604
- William B Klimstra$13,808,129
- Mark T Heise$26,876,746
- Aravinda M De Silva$31,411,437
Others in their field
Top investigators on “Replicon”
- Jonathan Smith · Alphavax Human Vaccines, Inc.$20,943,892
- Charles M. Rice · Rockefeller University$17,960,348
- Richard J. Kuhn · Purdue University$15,751,691
- Jeffrey D Chulay · Alphavax Human Vaccines, Inc.$13,968,680
- Barton F Haynes · Duke University$10,283,290
- Sujan Shresta · La Jolla Institute For Immunology$9,260,067
Research focus
RepliconVenezuelan Equine Encephalitis VirusVaccine DevelopmentVector VaccineAids VaccinesParticleInfectionVaccinesHuman Immunodeficiency Virus 1BaseProductionImmunizationVirusAdjuvantGenesCellsProteinsImmune ResponseResponseAntigensAlphavirusLymph NodesPathogenSignal Pathway
Grant awards (42)
A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus$532,838
R41 · FY2015 · AI · contact PI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$566,898
R01 · FY2014 · AI · contact PI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$532,884
R01 · FY2013 · AI · contact PI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$566,898
R01 · FY2012 · AI · contact PI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$385,121
R01 · FY2011 · AI · contact PI
A NOVEL SYSTEMIC AND MUCOSAL ADJUVANT FOR BIODEFENSE$100,951
P51 · FY2011 · RR · contact PI
A Novel Systemic and Mucosal Adjuvant for Biodefense$518,489
U01 · FY2010 · AI · contact PI
A NOVEL SYSTEMIC AND MUCOSAL ADJUVANT FOR BIODEFENSE$152,094
P51 · FY2010 · RR · contact PI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,175,233
U01 · FY2009 · AI · contact PI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,069,641
U01 · FY2009 · AI · contact PI
Alphavirus Vectored Vaccines for the SARS Coronavirus$295,521
P01 · FY2009 · AI · contact PI
A NOVEL SYSTEMIC AND MUCOSAL ADJUVANT FOR BIODEFENSE$142,267
P51 · FY2009 · RR · contact PI
Alphavirus Vectored Vaccines for the SARS Coronavirus$287,577
P01 · FY2008 · AI · contact PI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,166,198
U01 · FY2007 · AI · contact PI
Alphavirus Vectored Vaccines for the SARS Coronavirus$291,010
P01 · FY2007 · AI · contact PI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,244,356
U01 · FY2006 · AI · contact PI
Alphavirus Vectored Vaccines for the SARS Coronavirus$269,313
P01 · FY2006 · AI · contact PI
Therapeutic Vaccination for HIV Using VEE Vectors$1,394,294
P01 · FY2005 · AI
Alphavirus Vectored Vaccines for the SARS Coronavirus$218,610
P01 · FY2005 · AI
Therapeutic Vaccination for HIV Using VEE Vectors$1,413,970
P01 · FY2004 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV$997,238
P01 · FY2004 · AI
In vitro Construction of Attenuated VEE Virus Mutants$369,193
R01 · FY2004 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV$69,057
P01 · FY2004 · AI
Therapeutic Vaccination for HIV Using VEE Vectors$59,191
P01 · FY2004 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV$2,597,547
P01 · FY2003 · AI
Therapeutic Vaccination for HIV Using VEE Vectors$1,338,827
P01 · FY2003 · AI
In vitro Construction of Attenuated VEE Virus Mutants$358,440
R01 · FY2003 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV$2,414,394
P01 · FY2002 · AI
Therapeutic Vaccination for HIV Using VEE Vectors$1,390,608
P01 · FY2002 · AI
In vitro Construction of Attenuated VEE Virus Mutants$342,351
R01 · FY2002 · AI
First and second generation HIV-VRP vaccines$0
P01 · FY2002 · AI
LYMPH NODE TARGETING AND IMMUNOGENICITY$0
P01 · FY2002 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV$2,456,857
P01 · FY2001 · AI
Therapeutic Vaccination for HIV Using VEE Vectors$639,668
P01 · FY2001 · AI
In vitro Construction of Attenuated VEE Virus Mutants$326,617
R01 · FY2001 · AI
VRP IMMUNOGENICITY FOR A SECOND GENERATION VACCINE$0
P01 · FY2001 · AI
LYMPH NODE TARGETING AND IMMUNOGENICITY$0
P01 · FY2001 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV$2,389,569
P01 · FY2000 · AI
LYMPH NODE TARGETING AND IMMUNOGENICITY$403,624
P01 · FY2000 · AI
MOLECULAR BASIS OF ALPHAVIRUS NEUROVIRULENCE$294,511
R01 · FY2000 · AI
IN VITRO CONSTRUCTION OF ATTENUATED VEE VIRUS MUTANTS$269,014
R01 · FY2000 · NS
IN VITRO CONSTRUCTION OF ATTENUATED VEE VIRUS MUTANTS$64,020
R01 · FY2000 · NS